D-0179-2021 Class II Terminated

Recalled by Ascend Laboratories LLC — Parsippany, NJ

FDA drug recall D-0179-2021 was initiated by Ascend Laboratories LLC on Dec 17, 2020 and is designated Class II. Reason for recall: Failed Impurity/Degradation Specifications The recall status is terminated (terminated May 3, 2023). Affected quantity: 9,524 bottles.

Recall details

Product Type
Drugs
Report Date
Jan 6, 2021
Initiation Date
Dec 17, 2020
Termination Date
May 3, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
9,524 bottles

Product description

Ascend Laboratories, llc Cephalexin for Oral Suspension, USP 250 mg per 5 mL 200 ml (when mixed) Rx Only Manufactured by: Alkem Laboratories, Ltd, Mumbai -400 013 INDIA Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-545-68

Reason for recall

Failed Impurity/Degradation Specifications

Distribution pattern

Nationwide

Code information

20141680, 20141681, 20141759

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0179-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0179-2021. Report a data issue: hello@regdatalab.com.